公开(公告)号：US12115227B2

公开(公告)日：2024-10-15

申请号：US16069391

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Lene Schantz Harlow ,  Timothy Warren Paul ,  Brendan M. Mayhugh ,  Kelly Ann Roby ,  Gregory Allan Sacha ,  Xiaona Jing ,  Andrew Hagarman ,  Cale Halbleib

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/19 ,  A61K38/07 ,  A61K47/18 ,  A61K47/26 ,  A61K47/68 ,  A61K47/69 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K47/6849 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/07 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6921 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73

Abstract: Disclosed herein are surfactant free antibody and antibody-drug-conjugate (ADC) formulations for anti-AXL antibodies and ADCs, including aqueous formulations, lyophilized formulations, and reconstituted formulations, as well as related processes and uses. The formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some formulations comprise histidine and mannitol.